IASLC 2021 Board Slate of Candidates

We are pleased to share that the IASLC Board of Directors has approved the slate of candidates for the 2021 IASLC Board Election. Special thanks to the IASLC Nominating committee for their work and to those members who participated in the nomination process. Voting opens May 3, 2021.
Blue Image of the globe with hexagons around it

The IASLC Board of Directors chose this final list of candidates from the many qualified applicants based on the criteria listed below and the demographic needs to include regional, specialty, and gender balance of the IASLC Board to ensure a Board representative of our membership. 


Important Dates

March 15, 2021

Campaign period opens for candidates. 

May 3, 2021

2021 IASLC Board Election opens. 

June 14, 2021

2021 IASC Board Election closes at 9:59 Mountain Daylight Time (MDT)

Please watch for an email detailing voting procedures and access to the candidates’ information.

On May 3, 2021, all IASLC members with voting rights will receive an electronic ballot to cast your vote from Survey & Ballot Systems (SBS) who is administering the 2021 Board of Directors election. If you do not receive your election email by May 3, 2021, please contact [email protected] 

If your membership does not include voting rights, IASLC Membership will reach out to you with upgrading options via email communication in the coming weeks prior to voting opening. In the meantime, for questions or information on member voting eligibility, please contact [email protected]

As an IASLC Board member, how do you envision helping the organization adhere to its international and multidisciplinary mission? 

See the candidates' full answers below by clicking on the red + on the bottom of their block. 

President-Elect | One Seat, 2-Year Term

HEadshot of Dr. Van Shill

Paul Van Schil

Thoracic Surgeon, University Hospital of Antwerp, Antwerp,

As a thoracic surgeon, I have had a special interest in thoracic oncology for many years and as an active member of several international societies, I will try to strengthen not only the surgical input in IASLC but also the involvement of other minor specialties such as radiation oncology, pathology, radiology and nuclear imaging. Interaction with these related disciplines has to be intensified. This is critically important as these specialties represent quite a large group within the IASLC membership, and multidisciplinary cooperation is becoming increasingly important.  Equally, involvement of nurses, other health care workers and patient groups has to be stimulated further, as they represent the true core of our association. Further involvement of fellows and younger specialists will bring “new blood” into the society as they will build the future of our association. A good example is the Staging Committee where very recently, a call was launched for younger colleagues to participate in this committee and already prepare the 10th edition of the TNM classification.  I have learned much from previous board members and especially Dr. Giorgio Scagliotti and Dr. Tetsuya Mitsudomi who, as dedicated presidents, guided the IASLC through challenging times. I highly respect the incoming president, Dr. Heather Wakelee, for her great contributions and leadership in thoracic oncology. As our specialties are complimentary, I am convinced we are able to establish a strong executive committee and guide a truly international and dedicated board of directors. In this way, we will also be able to strengthen the scientific impact of IASLC.


Designated European Pulmonary | One Seat, 4-year term

Headshot of Dr. Aerts

Joachim Aerts

Erasmus University Medical Center, Rotterdam,

I envision helping the organization by using my experience and my enthusiasm for IASLC’s aims and missions. I strongly believe that an international and multidisciplinary team of experts can move the field towards a better treatment for our patients and achieve more in prevention. Global collaboration is essential nowadays, as we have learned from the COVID pandemic. The IASLC is the global organization bringing together all experts in the field of thoracic oncology, with the mission to study, educate, optimally treat, and eventually eliminate thoracic malignancies. This global coverage is, however, also complicated to manage given the differences between countries in culture, needs, treatment, and research options. I consider this a challenge which I want to work on, and my strong international experience will be helpful in this job.  I serve as Chair of IASLC’S Education Committee where we are working on global education and have initiated a plan for more regional educational programs to fill local needs. I consider a multidisciplinary team essential given the complexity of treatment, but even more important to make progress in treatment options. During my long-term international research projects on lung cancer and mesothelioma, with the integration of basic, translational, and clinical research, I have enjoyed collaborating with investigators and physicians from different countries and backgrounds. I believe this experience, along with my former leadership positions, will be helpful in the task of the board of directors.


Headshot of Dr. Huber

Rudolf Huber

Ludwig Maximilian University, Munich,

As an IASLC Board member, I would use my professional background and my long-standing work in respiratory and oncological societies for the IASLC - an international and multidisciplinary community. This approach is needed for conquering thoracic
malignancies worldwide. I would work to further increase respiratory knowledge in the society, foster the activities of respiratory physicians and researchers, and develop the collaboration of respiratory societies within the IASLC.

Headshot of Dr. Peled

Nir Peled

Ben Gurion University of the Negev, Beer Sheva,

As a board-certified pulmonologist, medical oncologist and as a KOL in precision oncology and translational research, I will support the IASLC leadership through my clinically relevant and field-related experience.  In addition, I will endorse the IASLC activities within my international network, which has expanded over the last decade across Europe, the Far East, the Middle East and America.  I see the IASLC as a leading organization in the field of thoracic malignancies as it combines all experts in a single room.  The multidisciplinary approach is mandatory to take us to the next level of precision care of lung cancer. The incorporation of highly sophisticated genomic platforms and the novel understanding of the immune dynamics are already here, and as such, we are already expanding our clinical partners. As a board member, I will bring this interaction into the daily activity of the IASLC. 

Designated Nurses & Allied Health Professionals | One Seat, 4-Year Term

Morton Quist

Morton Quist

University Hospital, Copenhagen,

My highest qualification to serve on the IASLC Board is the desire to improve the everyday life of patients with lung cancer. During my work and research, I have developed interventions (national and international) for early and advantage stage lung cancer with an aim of improving functional capacity and quality of life. All interventions are multidisciplinary, so the patient's perspectives are addressed with diversity. As a member on the IASLC Board, I would be the first allied health professional to serve the board and contribute to a multidisciplinary organization where multidisciplinary means an involvement of Nurses, Psychologists, Physiotherapists, Occupational therapists, Dietitians, etc. and an increased focus on patient-centered clinical intervention research, supportive care and palliation. etc. and an increased focus on patient-centered clinical intervention research, supportive care, and palliation.

Designated Latin America | One Seat, 4-Year Term

Headshot of Dr. Arrieta

Oscar Arrieta

The National Cancer Institute, Mexico City,

As an IASLC Board member, I would encourage the organization to improve participation from colleagues in Latin America from different strategies and perspectives. The IASLC is first and foremost an international organization which has a primary interest to improve the lives of patients with lung cancer despite the region they live in. I believe in equitable and accessible care for cancer
patients worldwide. Nonetheless, it is important that the needs of specific regions be addressed, and in order for this to happen those needs must first be understood and presented so that decisions can be made in order to achieve appropriate solutions. Latin America is many times poorly understood in terms of the difficulties faced by clinicians, patients, and researchers in the regions. I intend to work together with the IASLC to generate and promote research in LATAM, and also to ensure research is met with strategies to improve outcomes in patients from this region. In my experience, research drives both innovation and policy. Currently, Board Members from the region have worked tremendously in order to improve these challenging issues, and I envision myself continuing this mission while considering the experiences from past events in order to increase collaborative efforts in Latin America, both within the region and across other areas. Also, I would like to increase awareness of the many benefits of IASLC membership and stimulate enrollment for many specialists who would benefit from the many experiences offered to members. Last, it is important to increase participation in world-renowned events, including the WCLC, by colleagues from Latin America.

Headshot of Dr. Ferreira

Carlos Gil Moreira Ferreira

Oncoclinicas Institute, Rio de Janeiro,

To help the organization to adhere to its international and multidisciplinary mission, I intend:  to strengthen local anti-tobacco policies; to create forums and offer resources to discuss the challenges of doing research in South America and other developing areas including costs, regulatory issues, and difficulty in recruitment and to emphasize the many advantages of performing trials in developing countries such as availability of patients, lower costs and faster accrual; to increase the application of young fellows from LATAM and other developing areas to IASLC fellowship opportunities; to create forums to discuss strategies to improve access of lung cancer patients from developing countries to innovative diagnosis and therapy strategies; to significantly increase the number of Members from Latin America by creating close relationships with local Medical and Research Societies; and to continue promoting the LALCA Meetings, increasing the discussion of local issues.   

Medical Oncology: North America | One Seat, 4-Year Term

Headshot Dr. Edelman

Martin Edelman

Fox Chase Cancer Center, Philadelphia, Pennsylvania,
United States

Over the years I have had many opportunities to meet with colleagues across a wide spectrum of institutions and organizations, both within the U.S. and abroad. I believe that I have developed a broad view and approach to the issues that face all of us and an appreciation for the many and varied issues that confront us both in practice and research.  I have a strong interest in education and career development. I am particularly interested in assisting members from institutions and countries that may not have well-developed programs in thoracic oncology.  Improving opportunities for research and education to these individuals both enhances their careers as well as patient outcomes. I will bring over 30 years of experience in clinical practice, research, and education to the board. In addition, my experience in administration at multiple institutions and in multiple settings will be an asset to the Board.



Headshot of Dr. Osarogiagbon

Ray Osarogiagbon

Baptist Memorial Health Care Corporation, Memphis, Tennessee,
United States

I am a practicing Thoracic Medical Oncologist and Chief Scientist in a large community-based healthcare system in the US. I am also a multi-cycle NIH- and PCORI-funded researcher. My team’s main purpose has been to improve cancer care delivery in the places where quality improvement would be most impactful. We conducted Implementation Science on surgical and pathology quality improvement, work that has contributed to the adoption of ‘Operative Standard 5.8’ by which lung cancer programs accredited by the Commission on Cancer will be evaluated from 2021 onward. In more recent work, we are examining the population level impact of tandem dissemination of incidental lung nodule and low-dose CT lung cancer screening programs.

My research has benefited from strong collaborations with colleagues in North and South America, Europe, and China. We have worked closely with patient advocacy groups to elevate the patient voice in lung cancer. Formative training in Nigeria also provided me with insights into the unique challenges of delivering high-quality cancer care in low- and middle-income countries.

If elected to the Board, I plan to use the hard-won insights from my diverse experiences to help the IASLC’s mission to Conquer Thoracic Cancers worldwide. I believe our purpose is to ‘make lung cancer go away and never come back' at both the individual and population levels. Our challenge is not only to discover, but also to disseminate and implement discoveries; to open access to all people endangered by cancer, irrespective of who they are. Irrespective of where they live.

Headshot of Dr. Sequist

Lecia Sequist

Massachusetts General Hospital, Boston, Massachusetts,
United States

I am honored to be on the 2021 election slate for the IASLC Board of Directors among a list of very esteemed peers. I would like to share my motivations for serving the organization and its members in this capacity. We are making unprecedented progress as a field, but our patients still face daily stigma and roadblocks in accessing recommended care. Lung cancer screening is a powerful tool which could save hundreds of thousands of lives and yet it is woefully under-utilized. I have the knowledge and experience to grow and strengthen multidisciplinary teams, skills I have acquired over the last 17 years working in lung cancer patient care, translational research and team science, scientific grant writing, manuscript publishing, peer/editorial review, education, mentoring and patient advocacy.  I am especially committed to bringing new voices to the conversation. I place high value on the international aspect of IASLC and know that through involvement in the board I can personally dive in to increase equity for both lung cancer professionals but more importantly, for patients with lung cancer around the world.  Finally, I am passionate about developing the next generation of diverse leaders in our field, equipped with a broad set of tools. They will need to be fluent not only with cutting-edge research and clinical care skills, but also with specific training to effectively engage the public, policymakers, survivors, and advocates in a global conversation about eliminating lung cancer. I have never been more excited to be part of this vibrant community and would be honored to serve the IASLC community as a board member.

Pathology | One Seat, 4-Year Term

Headshot of Dr. Dacic

Sanja Dacic

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania,
United States

Pathologists are valuable members of multidisciplinary teams diagnosing, treating, and investigating lung cancer and other thoracic malignancies. As a member of the IASLC Board, I will bring a unique perspective and help to implement new multidisciplinary projects to further enhance IASLC’s international leadership in the field of thoracic malignancies. I have served on the IASLC Pathology Committee, and in all of my past work, I initiated, actively participated in, and executed both pathology and interdisciplinary projects. In addition to my direct work with specific diseases, I have also spent much of my career helping to build alliances and strategic partnerships between different organizations. As president of the Pulmonary Pathology Society (PPS), a partner society of the IASLC, I believe I can further promote engagement of PPS members and our partner societies around the globe and further grow the footprint and strength of IASLC. Through my connections with influencers in social media, I would like to use these platforms to access diverse international societies and also engage early-career physicians, trainees, and future leaders in the field of thoracic malignancies. Modern educational delivery methods using digital assets and even social media platforms became a new norm during a pandemic. We can continue this powerful trajectory and extend our outreach to colleagues working in low-resource countries. This is a great opportunity to create multidisciplinary educational activities for IASLC members, partner societies, our patients, and other stakeholders. My inclusive leadership style, my focus on team engagement, and my ability to broker common ground between disparate stakeholders would all allow me to serve the IASLC Board. 


Headshot of Dr. Tsao

Ming Sound Tsao

Princess Margaret Cancer Centre, Toronto, Ontario,

Pathology and biomarkers play critical roles in the implementation of precision oncology. During the last decade, the IASLC Pathology Committee have played leadership roles in improving the classification of thoracic malignancies (WHO classification book on Thoracic Tumors), standardization of biomarker assays (Blueprint projects), and knowledge transfer on optimal pathology and biomarker practices (Atlases, webinars and white papers on biomarker testing). These efforts were taken in collaboration with many global academic and industrial partners. However, a recent global survey by the IASLC still revealed significant continental and regional disparities in biomarker testing. With experience leading many of the IASLC Pathology Committee initiatives, I shall be a strong advocate on ways and means for greater integration of pathology and biomarker testing to advance global quality of thoracic cancer diagnosis and treatment, through multidisciplinary and multilateral collaboration and research projects. I shall also promote ideas in making IASLC and its publications as the priority knowledge resource for all involved in the care, diagnosis, treatment, education, and research of thoracic malignancies.

Headshot of yasushi yatabe

Yasushi Yatabe

National Cancer Center Hospital, Tokyo,

IASLC members understand state-of-the-art diagnosis and treatment for thoracic malignancies, many of which have been achieved in member research projects. However, it is difficult to put them all into clinical practice because of healthcare system regulations, financial issues, inappropriate bridging between research and treatment, and lack of specialized education, as well as other factors. The IASLC is the only international scientific society dedicated to the study of thoracic malignancies via a multidisciplinary approach, thus our strength is based on activities with multidisciplinary worldwide members like a united package from research to treatments. Similar to our previous achievements, the IASLC should lead in promotion of new standards, while the establishment of minimum standards is also essential. Such attempts by our global multidisciplinary organization can drive local regulatory bodies to raise standards to a higher level. In particular, in this COVID-19 pandemic era, the IASLC should be able to take a leading role to support healthcare professionals. I would like to contribute to developing an environment where effective cancer treatment can be delivered to patients as efficiently as possible, which would include pooling of knowledge presented in our journals, sharing experiences, and spreading information via SNS. Furthermore, the IASLC should support participation in registration studies, such as TERAVOLT, which are investigating risk factors for COVID-19-related deterioration of clinical conditions, serum biochemical data, cancer staging, treatment types, and other important issues related to safe and effective treatment of cancer patients.

Asia/Rest of World | One Seat, 4-Year Term

Headshot of Dr.pavlakis

Nick Pavlakis

Royal North Shore Hospital, St. Leonards,

The IASLC is the premier multi-disciplinary international organization bringing people together with the common aim to “conquer thoracic cancers”. Since joining in 2004 I have valued the collegiality and multidisciplinary focus of the IASLC, forming friendships and research collaborations across the globe. The fact that lung cancer continues to be the leading global cancer emphasizes the importance of the IASLC in tackling the problem at a global level. Whilst we cannot dictate individual country policy, we can advocate to fulfill the continuing unmet need to invest in lung cancer research, screening, and treatment, identify gaps and promote excellence in research and training while promoting practice guidelines and advocating for equity of care across the globe. The IASLC must lead by example. As the son of migrant parents, I didn't grow up with privilege, yet as an Australian I am privileged. As in the global sporting arena, I feel accustomed to being the underdog, in the same way, that lung cancer patients feel compared to their more well-supported cancer cousins with breast, prostate, and bowel cancers as examples. The global oversight of lung cancer prevention, research, and treatment needs a balanced perspective in order to have a meaningful impact. Collaboration is key, regardless of politics. It is important that the IASLC’s voice is not one for the privileged but for all. I hope to bring my own sense of collegiality, interpersonal skills, passion, and a broad perspective to the Board in order to help it fulfill the global mission of the IASLC.

Headshot of Dr. Kim

Young Tae Kim

Seoul National University, Republic of Korea,
South Korea

The recent development of target agents and immunotherapies and the discovery of the genomic alteration of lung cancer is drawing the attention of many IASLC members. However, many surgeons have not fully given their attention to these developments, as their primary interests remain focused on developing their surgical skills. Nevertheless, knowledge of lung cancer genomics has become essential to understanding lung cancer's biological behavior and designing effective treatment plans. As a surgeon, I had the opportunity to collaborate with basic researchers and achieve fruitful discoveries in the area of lung cancer genomics and immunotherapies. Based on my experience, I can develop diverse IASLC programs that will attract the attention of surgeons. I also believe the IASLC should take practical measures to reach out to currently underrepresented geographic regions and developing countries where support from the IASCL is needed. Through my work with the AATS and Women in Thoracic Surgery, I established educational travel scholarships for doctors in developing countries, an effective outreach approach that expanded participation for underrepresented groups in important educational programs. I believe that my broad experience has prepared me well for a possible new role as an IASLC Board member. If I am given the opportunity to serve on the IASLC Board, I will do my best to lead the IASLC to step forward and carry out the initiatives outlined above.

Medical Oncology: Open | One Seat, 4-Year Term

Headshot of Dr. Capuzzo

Federico Cappuzzo

The National Cancer Institute, Regina Elena, Rome,

For many years, the IASLC has conducted many activities that promote a multidisciplinary approach in thoracic cancers, including conferences, meetings and educational activities. The COVID pandemic is now dramatically impacting all face-to-face events and we are now shifting to a web modality that is reducing the interaction between experts, even if it is facilitating participation. Irrespective of the duration of the Covid pandemic, the way in which international and multidisciplinary activity will be conducted in the future is changing. As an IASLC board member, I will promote events and educational activities that increase the number of IASLC affiliates. These activities will include events involving specialists in different therapy areas as well as caregivers and nurses, using virtual or hybrid formats. I will contribute by promoting clinical trials with a special focus on translational research and integrated therapies. In addition, I will work on a systematic data collection from different geographic areas, aiming at defining differences in diagnosis and therapy approaches.

shirish gadgeel

Shirish Gadgeel

Henry Ford Cancer Institute, Detroit, Michigan
United States

The IASLC Board has a critical role in ensuring that the organization is focused on fulfilling its mission. Lung cancer, in particular, and thoracic malignancies in general are a major healthcare problem in the world. Among many issues, access to preventive and therapeutic measures is the most critical. This should be addressed through education, research and global outreach. The Board needs to play a pivotal role in both guiding and monitoring the activities of IASLC. IASLC does an excellent job in conducting a premier Thoracic Oncology Annual Meeting and publishing a high-impact factor journal. Its initiatives in global outreach and education are commendable but need to be enhanced. Its engagement with Thoracic Surgery, Pulmonologists, Pathologists could be improved upon. In addition, a greater engagement with primary care physicians with the goal of improving lung cancer screening rates and implementing lung cancer survivorship programs would be very critical. A great barrier to care of lung cancer and other thoracic cancer patients is the ability to provide access to appropriate molecular testing and access to modern drugs and technology. IASLC, with the guidance of the IASLC Board, has an important role in breaking down these barriers by working with industry, governments, and other members of the health care infrastructure. I believe my experiences over the last 20 years in various aspects of the care of lung cancer patients, as well my engagements with ASCO, IASLC and SWOG will serve me well in helping the IASLC to achieve the above-stated goals and remain focused on improving the care of Thoracic Oncology patients across the globe.

Headshot of Dr. Gray

Jhanelle Gray

Moffitt Cancer Center, Tampa, Florida,
United States

Since 1974, the IASLC is the premier global network dedicated to the study and eradication of lung cancer and thoracic malignancies. With a mission to embrace the multi-dimensional study of lung cancer, to provide education about lung cancer to the medical community and public, and to use all available means to eliminate lung cancer, this position aligns with my own ideals and aspirations of improving patient care and access, partnering with providers, other health care professionals, and patients as well as expanding the impact of research across global communities.  Further, this position provides the opportunity to continue to give back, engage, and mentor members across various disciplines and formulate ways to shape priorities to help advance IASLC’s mission.  By identifying and collaborating with key stakeholders and offering diverse platforms in which ideas can be exchanged, we can overcome barriers together and the scope of our impact can expand exponentially.  As an IASLC Board member, l will help drive the pace and direction of the Association and help orchestrate the strategic plan to best accomplish goals and objectives.  I am dedicated to the IASLC mission and hope to have the opportunity to further build on what has previously been created, thereby leveraging my skills, experience, and talents to be an asset to the position and to IASLC.

Multi-Specialty, Multi-Region, Female | One Seat, 4-Year Term

jose belderbos

José Belderbos

The Netherlands Cancer Institute, Amsterdam,

The IASLC has challenging times ahead. First, the importance of a multidisciplinary approach for lung cancer is crucial. As a radiation oncologist working at the Netherlands Cancer Institute, I have vast experience interacting with patients and colleagues from other specialties. Secondly, the COVID pandemic will challenge the IASLC organization that is 'like a family' but has grown enormously over the past decade. I intend to focus on how to keep these familiar worldwide connections in a COVID-restricted world. Third, I am an advocate for the translation of results from trials to the general lung cancer population. Oftentimes doctor reported outcomes are endpoints in patients selected for a trial. We must consider the patient's reported outcomes as well as real-world data in our models to improve the prediction of treatment efficacy and toxicity. Lastly, I believe efforts should be made in all countries to provide the lowest radiation side effects by sophisticated radiotherapy techniques. My contributions in the ESTRO-UP Lung project is helping to analyze the utilization of radiotherapy for lung cancer in Europe. I aim to extend this to a worldwide analysis.

emily stone

Emily Stone

St. Vincent's Hospital, Sydney,

I would help the IASLC adhere to its international purposes as a voice from the Australian/Asia-Pacific.  I am also committed to international collaboration in my own research and through my work with IASLC and other international committees. I would look to continue this with IASLC Board duties, benefitting from the experiences and insights of people who work all around the world. I would help the IASLC with its multidisciplinary mission as a representative of pulmonary medicine, a smaller specialty group within the IASLC. My particular research areas of tobacco control and smoking cessation, multidisciplinary team care, and lung cancer screening cross multiple disciplines and allow me to develop good working relationships with colleagues from many different areas. I would view my role on the Board as a continuation of my current professional approach—cooperative, open to opportunity, and focused on collective achievements.

paula ugalde

Paula Ugalde

University Institute of Cardiology & Pneumology, Quebec City,

I am recognized as an international mentor within the Women in Thoracic Surgery organization, and I have the experience of working in numerous countries, including Canada, the US and Brazil with linguistic fluency in four languages. I believe my multi-national reach is an important asset and is emblematic of the mission of the IASLC, which includes international education. I have a large international network in South America and North America, and I will dedicate my work to stimulate international cooperation (attract members, inclusion in prospective database, education, large studies, attract people to meetings and WCLC). I also want to integrate thoracic surgery within IASLC, with a special attention to women in thoracic surgery (staging, combined modality treatment, publications, education of surgeons e.g., lymph node dissection). We must devote time to help women advance in their academic career and identify role models to stimulate young surgeons to devote their aim for excellence.

2021 Board of Directors Slate of Candidates

Image of IASLC logo on background with globe
Board of Directors
Download (1.86 MB)

IASLC Board of Directors Testimonials

Tetsuya Mitsudomi
Tetsuya Mitsudomi | IASLC President 2019 - 2021
We must realize that there is a significant disparity in the world in terms of diagnosis and treatment, and thus treatment outcomes of lung cancer. It is very important for the IASLC as an international society to reduce these differences as much as possible.
Heather Wakelee
Heather Wakelee | IASLC President-Elect 2019 - 2021
My interest in IASLC has also been strengthened by the value I place on the international aspects of the discussions. It has been so amazing for me personally to realize that there are people all around the world with parallel lives to mine—they are physicians dedicated to treating patients with lung cancer and they face a lot of the same challenges as me and share the same sense of excitement while witnessing these incredible advances in the field.